Clinical development of nintedanib for advanced non-small-cell lung cancer

Pharmacology, Toxicology and Pharmaceutical Science

• Nintedanib 100%
• Non Small Cell Lung Cancer 66%
• Docetaxel 50%
• Monotherapy 33%
• Toxicity 16%
• Incidence 16%
• Adverse Event 16%
• Vasculotropin 16%
• Malignant Neoplasm 16%
• Combination Therapy 16%
• Metastasis 16%
• Receptor 16%
• Neoplasm 16%
• Aspartate Aminotransferase 16%
• Platelet Derived Growth Factor 16%
• Progression Free Survival 16%
• Overall Survival 16%
• Lung Cancer 16%
• Adenocarcinoma 16%
• Hepatotoxicity 16%
• Clinical Trial 16%
• Protein Tyrosine Kinase Inhibitor 16%
• Alanine Aminotransferase 16%
• Diarrhea 16%
• Angiogenesis Inhibitor 16%
• Fibroblast Growth Factor 16%